Amadori and Heyns rearrangement products of bioactive peptides as potential new ligands of galectin-3
Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3...
Saved in:
Published in | Carbohydrate research Vol. 542; p. 109195 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
01.08.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3 acts as a receptor for AGEs and some early products of the Maillard reaction. The early phase of the Maillard reaction, which consists of 1-amino-1-deoxyketoses (Amadori compounds) and 2-amino-2-deoxyaldoses (Heyns compounds), was the subject of our study. The binding interactions between galectin-3 and the Amadori and Heyns compounds of leucine-enkephalin (YGGFL), leucine-enkephalin methyl ester (YGGFL-OMe), truncated enkephalin (YGG and Y) and tetrapeptide (LSKL) were measured using the AlphaScreen competitive binding assay. The affinity of galectin-3 for Amadori and Heyns compounds depends on both the sugar moiety and the amino acid sequence of the model compounds. The best results were obtained with Leu-enkephalin derivatives of Amadori (IC50 = 6.06 μm) and Heyns (IC50 = 8.6 μm) compound, respectively.
[Display omitted]
•The interactions between Amadori and Heyns compounds of Leu-enkephalin and the tetrapeptide Leu-Ser-Lys-Leu with galectin-3 were investigated.•The AlphaScreen competitive binding assay was used to study the interactions of Amadori and Heyns compounds with galectin-3.•The Heyns compounds showed a higher affinity for galectin-3 compared to Amadori compounds.•The lack of the aromatic residues within the peptide sequence, showed a significantly lower affinity for galectin-3. |
---|---|
AbstractList | Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3 acts as a receptor for AGEs and some early products of the Maillard reaction. The early phase of the Maillard reaction, which consists of 1-amino-1-deoxyketoses (Amadori compounds) and 2-amino-2-deoxyaldoses (Heyns compounds), was the subject of our study. The binding interactions between galectin-3 and the Amadori and Heyns compounds of leucine-enkephalin (YGGFL), leucine-enkephalin methyl ester (YGGFL-OMe), truncated enkephalin (YGG and Y) and tetrapeptide (LSKL) were measured using the AlphaScreen competitive binding assay. The affinity of galectin-3 for Amadori and Heyns compounds depends on both the sugar moiety and the amino acid sequence of the model compounds. The best results were obtained with Leu-enkephalin derivatives of Amadori (IC₅₀=6.06 μm) and Heyns (IC₅₀=8.6 μm) compound, respectively. Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3 acts as a receptor for AGEs and some early products of the Maillard reaction. The early phase of the Maillard reaction, which consists of 1-amino-1-deoxyketoses (Amadori compounds) and 2-amino-2-deoxyaldoses (Heyns compounds), was the subject of our study. The binding interactions between galectin-3 and the Amadori and Heyns compounds of leucine-enkephalin (YGGFL), leucine-enkephalin methyl ester (YGGFL-OMe), truncated enkephalin (YGG and Y) and tetrapeptide (LSKL) were measured using the AlphaScreen competitive binding assay. The affinity of galectin-3 for Amadori and Heyns compounds depends on both the sugar moiety and the amino acid sequence of the model compounds. The best results were obtained with Leu-enkephalin derivatives of Amadori (IC50 = 6.06 μm) and Heyns (IC50 = 8.6 μm) compound, respectively. [Display omitted] •The interactions between Amadori and Heyns compounds of Leu-enkephalin and the tetrapeptide Leu-Ser-Lys-Leu with galectin-3 were investigated.•The AlphaScreen competitive binding assay was used to study the interactions of Amadori and Heyns compounds with galectin-3.•The Heyns compounds showed a higher affinity for galectin-3 compared to Amadori compounds.•The lack of the aromatic residues within the peptide sequence, showed a significantly lower affinity for galectin-3. Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3 acts as a receptor for AGEs and some early products of the Maillard reaction. The early phase of the Maillard reaction, which consists of 1-amino-1-deoxyketoses (Amadori compounds) and 2-amino-2-deoxyaldoses (Heyns compounds), was the subject of our study. The binding interactions between galectin-3 and the Amadori and Heyns compounds of leucine-enkephalin (YGGFL), leucine-enkephalin methyl ester (YGGFL-OMe), truncated enkephalin (YGG and Y) and tetrapeptide (LSKL) were measured using the AlphaScreen competitive binding assay. The affinity of galectin-3 for Amadori and Heyns compounds depends on both the sugar moiety and the amino acid sequence of the model compounds. The best results were obtained with Leu-enkephalin derivatives of Amadori (IC = 6.06 μm) and Heyns (IC = 8.6 μm) compound, respectively. Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3 acts as a receptor for AGEs and some early products of the Maillard reaction. The early phase of the Maillard reaction, which consists of 1-amino-1-deoxyketoses (Amadori compounds) and 2-amino-2-deoxyaldoses (Heyns compounds), was the subject of our study. The binding interactions between galectin-3 and the Amadori and Heyns compounds of leucine-enkephalin (YGGFL), leucine-enkephalin methyl ester (YGGFL-OMe), truncated enkephalin (YGG and Y) and tetrapeptide (LSKL) were measured using the AlphaScreen competitive binding assay. The affinity of galectin-3 for Amadori and Heyns compounds depends on both the sugar moiety and the amino acid sequence of the model compounds. The best results were obtained with Leu-enkephalin derivatives of Amadori (IC50 = 6.06 μm) and Heyns (IC50 = 8.6 μm) compound, respectively.Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3 acts as a receptor for AGEs and some early products of the Maillard reaction. The early phase of the Maillard reaction, which consists of 1-amino-1-deoxyketoses (Amadori compounds) and 2-amino-2-deoxyaldoses (Heyns compounds), was the subject of our study. The binding interactions between galectin-3 and the Amadori and Heyns compounds of leucine-enkephalin (YGGFL), leucine-enkephalin methyl ester (YGGFL-OMe), truncated enkephalin (YGG and Y) and tetrapeptide (LSKL) were measured using the AlphaScreen competitive binding assay. The affinity of galectin-3 for Amadori and Heyns compounds depends on both the sugar moiety and the amino acid sequence of the model compounds. The best results were obtained with Leu-enkephalin derivatives of Amadori (IC50 = 6.06 μm) and Heyns (IC50 = 8.6 μm) compound, respectively. |
ArticleNumber | 109195 |
Author | Cudic, Mare Ayyalasomayajula, Ramya Jakas, Andreja |
Author_xml | – sequence: 1 givenname: Andreja orcidid: 0000-0001-6095-7515 surname: Jakas fullname: Jakas, Andreja email: Andreja.Jakas@irb.hr organization: Rudjer Bošković Institute, Division of Organic Chemistry and Biochemistry, Bijenička c. 54, 10000, Zagreb, Croatia – sequence: 2 givenname: Ramya orcidid: 0000-0002-7610-0097 surname: Ayyalasomayajula fullname: Ayyalasomayajula, Ramya organization: Florida Atlantic University, Department of Chemistry and Biochemistry, 777 Glades Rd., Boca Raton, FL, 33431, USA – sequence: 3 givenname: Mare surname: Cudic fullname: Cudic, Mare email: mcudic@fau.edu organization: Florida Atlantic University, Department of Chemistry and Biochemistry, 777 Glades Rd., Boca Raton, FL, 33431, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38908217$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU9rFTEUxYNU7Gv1G4hk6WZe82-SjAuhFLWFghsFdyEvufPIYyYZk7yWfntTp924sKtww-8c7j3nDJ3EFAGh95RsKaHy4rB1NmcoW0aYaF8DHfpXaEO14p1g8tcJ2hBCdCcZ7U_RWSmHNhKp5Bt0yvVANKNqg-Bytj7lgG30-BoeYsEZmq-Ne5ghVrzk5I-uFpxGvAvJuhruAC-w1OChYFvwkmoDg51whHs8hX2z-ovv7QQNjx1_i16Pdirw7uk9Rz-_fvlxdd3dfv92c3V52zk-9LUbueKSSS00tVRyRiQfJR846XvihdaghB6d970iSu9Ail5IxdoxwEDzgfFz9HH1bVv_PkKpZg7FwTTZCOlYDKc9l1IMRL2MEkWZ5pzShn54Qo-7GbxZcphtfjDPKTbg0wq4nErJMBoXqq0hxZptmAwl5rEyczBrZeaxMrNW1sTiH_Gz_wuyz6sMWp53AbIpLkB04ENuqRufwv8N_gBfpbAT |
CitedBy_id | crossref_primary_10_3390_molecules30020226 |
Cites_doi | 10.1039/P29960000789 10.1155/2012/894605 10.1021/bi051144z 10.3390/cells10113047 10.1080/14728222.2019.1675638 10.1074/jbc.M109.098160 10.1046/j.1523-1755.2000.07706.x 10.1016/S0304-4165(97)00086-X 10.1002/psc.1029 10.1021/acsmedchemlett.9b00540 10.1016/j.str.2010.05.017 10.1016/j.carres.2008.07.003 10.1056/NEJMsb1503104 10.1002/bip.10338 10.1002/psc.519 10.1021/acs.jmedchem.7b00058 10.1093/glycob/cwj056 10.1093/glycob/cwu111 10.3390/nu9080835 10.1007/s10719-020-09951-x 10.1016/j.ab.2013.04.028 10.1023/B:GLYC.0000014072.34840.04 10.1016/j.ccell.2019.06.006 10.1093/glycob/cwv073 10.1007/BF00053899 10.1152/ajpcell.00089.2020 10.1186/s12014-017-9146-0 10.1158/0008-5472.CAN-07-3233 10.1096/fj.04-2031fje 10.1007/BF03401604 10.1021/acs.biochem.5b00555 10.1002/rcm.7775 |
ContentType | Journal Article |
Copyright | 2024 Elsevier Ltd Copyright © 2024 Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: 2024 Elsevier Ltd – notice: Copyright © 2024 Elsevier Ltd. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 |
DOI | 10.1016/j.carres.2024.109195 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | AGRICOLA MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry |
EISSN | 1873-426X |
ExternalDocumentID | 38908217 10_1016_j_carres_2024_109195 S0008621524001745 |
Genre | Journal Article |
GroupedDBID | --- --K --M -~X .55 .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29B 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM 9JN AABNK AACTN AAEDT AAEDW AAHBH AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARLI AAXUO ABFNM ABGSF ABJNI ABMAC ABUDA ABXDB ACDAQ ACGFS ACNCT ACNNM ACRLP ADBBV ADECG ADEZE ADMUD ADUVX AEBSH AEHWI AEKER AENEX AFFNX AFKWA AFTJW AFXIZ AFZHZ AGHFR AGRDE AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AJSZI AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FLBIZ FNPLU FYGXN G-Q GBLVA HMS HVGLF HZ~ H~9 IHE J1W KOM M2Z M41 MO0 MVM N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG RNS ROL RPZ SCB SDF SDG SDP SES SEW SOC SPC SPCBC SSK SSU SSZ T5K WUQ X7M XPP Y6R YK3 ZXP ~02 ~G- ~KM AATTM AAXKI AAYWO AAYXX ABWVN ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKYEP ANKPU APXCP BNPGV CITATION SSH CGR CUY CVF ECM EFKBS EIF NPM 7X8 7S9 L.6 |
ID | FETCH-LOGICAL-c395t-f3736268481a1632063f63930550d488e748fcdd57078be6454672389e2e83923 |
IEDL.DBID | .~1 |
ISSN | 0008-6215 1873-426X |
IngestDate | Wed May 21 16:29:23 EDT 2025 Mon Jul 21 11:21:05 EDT 2025 Mon Jul 21 06:06:47 EDT 2025 Tue Jul 01 04:05:13 EDT 2025 Thu Apr 24 23:11:04 EDT 2025 Sat Jul 20 16:36:03 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Maillard reaction Amadori compounds Galectin-3 Leu-enkephalin AlphaScreen Heyns compounds |
Language | English |
License | Copyright © 2024 Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c395t-f3736268481a1632063f63930550d488e748fcdd57078be6454672389e2e83923 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-6095-7515 0000-0002-7610-0097 |
PMID | 38908217 |
PQID | 3071283311 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_3153664907 proquest_miscellaneous_3071283311 pubmed_primary_38908217 crossref_citationtrail_10_1016_j_carres_2024_109195 crossref_primary_10_1016_j_carres_2024_109195 elsevier_sciencedirect_doi_10_1016_j_carres_2024_109195 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-08-01 |
PublicationDateYYYYMMDD | 2024-08-01 |
PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Carbohydrate research |
PublicationTitleAlternate | Carbohydr Res |
PublicationYear | 2024 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Teodorowicz, Van Neerven, Savelkoul (bib13) 2017; 9 Koch, Chitayat, Dattilo, Schiefner, Diez, Chazin, Fritz (bib6) 2010; 18 FitzGerald, Rodriguez Benavente, Garcia, Rivero, Singh, Wang, Fields, Cudic (bib35) 2020; 37 Iacobini, Menini, Oddi, Ricci, Amadio, Pricci, Olivieri, Sorcini, Di Mario, Pesce, Pugliese (bib21) 2004; 18 Chuah, Basir, Talib, Tie, Nordin (bib10) 2013; 2013 Nangia-Makker, Raz, Tait, Hogan, Fridman, Raz (bib18) 2007; 67 Pricci, Leto, Amadio, Iacobini, Romeo, Cordone, Gradini, Barsotti, Liu, Di Mario, Pugliese (bib24) 2000; 58 Soares, Al-Dalahmah, Hillis, Young, Asbed, Sakaguchi, O'Neill, Szele (bib29) 2021; 10 Buckle, Forbes (bib7) 2023 Pugliese, Iacobini, Pesce, Menini (bib20) 2015; 25 Suto, Gupta, Mathew, Zhang, Pallero, Murphy-Ullrich (bib31) 2020; 11 Horvat, Jakas (bib1) 2004; 10 Jovanović, Peter‐Katalinić (bib11) 2017; 31 Isenberg, Roberts (bib30) 2020; 319 Glinsky, Mossine, Price, Bielenberg, Glinsky, Ananthaswamy, Feather (bib32) 1996; 14 Jakas, Katić, Bionda, Horvat (bib4) 2008; 343 Ochieng (bib19) 1998; 1379 Leffler, Carlsson, Hedlund, Qian, Poirier (bib16) 2002; 19 Mereiter, Balmaña, Campos, Gomes, Reis (bib26) 2019; 36 Rodriguez, Yegorova, Pitteloud, Chavaroche, André, Ardá, Minond, Jiménez-Barbero, Gabius, Cudic (bib34) 2015; 54 Cullen, Cascella (bib27) 2024 Jan Win, Yamamoto, Munesue, Saito, Han, Motoyoshi, Kamal, Ohara, Watanabe, Yamamoto (bib9) 2012; 2012 Vlassara, Li, Imani, Wojciechowicz, Yang, Liu, Cerami (bib12) 1995; 1 Ho, Springer (bib17) 1982; 128 Miller, Ippel, Suylen, Klyosov, Traber, Hackeng, Mayo (bib36) 2016; 26 Romero, Gabius (bib15) 2019; 23 Jakas, Horvat (bib3) 1996; 2 Bongarzone, Savickas, Luzi, Gee (bib8) 2017; 60 Nielsen, Østergaard, Rasmussen, Jacobsen, Heegaard (bib22) 2017; 14 Yegorova, Chavaroche, Rodriguez, Minond, Cudic (bib33) 2013; 439 Salomonsson, Carlsson, Osla, Hendus-Altenburger, Kahl-Knutson, Öberg, Sundin, Nilsson, Nordberg-Karlsson, Nilsson, Karlsson, Rini, Leffler (bib37) 2010; 285 Jakas, Horvat (bib2) 2003; 69 Jakas, Vinković, Smrečki, Šporec, Horvat (bib5) 2008; 14 Jameson, Longo (bib25) 2015; 372 Khawaja, Green, Thorpe, Titheradge (bib28) 1990; 267 Rabinovich, Cumashi, Bianco, Ciavardelli, Iurisci, D'Egidio, Piccolo, Tinari, Nifantiev, Iacobelli (bib14) 2006; 16 Dam, Gabius, André, Kaltner, Lensch, Brewer (bib23) 2005; 44 Iacobini (10.1016/j.carres.2024.109195_bib21) 2004; 18 Horvat (10.1016/j.carres.2024.109195_bib1) 2004; 10 Nangia-Makker (10.1016/j.carres.2024.109195_bib18) 2007; 67 Yegorova (10.1016/j.carres.2024.109195_bib33) 2013; 439 Jakas (10.1016/j.carres.2024.109195_bib2) 2003; 69 Rodriguez (10.1016/j.carres.2024.109195_bib34) 2015; 54 Glinsky (10.1016/j.carres.2024.109195_bib32) 1996; 14 FitzGerald (10.1016/j.carres.2024.109195_bib35) 2020; 37 Miller (10.1016/j.carres.2024.109195_bib36) 2016; 26 Teodorowicz (10.1016/j.carres.2024.109195_bib13) 2017; 9 Suto (10.1016/j.carres.2024.109195_bib31) 2020; 11 Pugliese (10.1016/j.carres.2024.109195_bib20) 2015; 25 Jakas (10.1016/j.carres.2024.109195_bib4) 2008; 343 Soares (10.1016/j.carres.2024.109195_bib29) 2021; 10 Jakas (10.1016/j.carres.2024.109195_bib3) 1996; 2 Buckle (10.1016/j.carres.2024.109195_bib7) 2023 Rabinovich (10.1016/j.carres.2024.109195_bib14) 2006; 16 Mereiter (10.1016/j.carres.2024.109195_bib26) 2019; 36 Isenberg (10.1016/j.carres.2024.109195_bib30) 2020; 319 Jameson (10.1016/j.carres.2024.109195_bib25) 2015; 372 Vlassara (10.1016/j.carres.2024.109195_bib12) 1995; 1 Ochieng (10.1016/j.carres.2024.109195_bib19) 1998; 1379 Romero (10.1016/j.carres.2024.109195_bib15) 2019; 23 Salomonsson (10.1016/j.carres.2024.109195_bib37) 2010; 285 Koch (10.1016/j.carres.2024.109195_bib6) 2010; 18 Khawaja (10.1016/j.carres.2024.109195_bib28) 1990; 267 Leffler (10.1016/j.carres.2024.109195_bib16) 2002; 19 Nielsen (10.1016/j.carres.2024.109195_bib22) 2017; 14 Jovanović (10.1016/j.carres.2024.109195_bib11) 2017; 31 Ho (10.1016/j.carres.2024.109195_bib17) 1982; 128 Chuah (10.1016/j.carres.2024.109195_bib10) 2013; 2013 Bongarzone (10.1016/j.carres.2024.109195_bib8) 2017; 60 Jakas (10.1016/j.carres.2024.109195_bib5) 2008; 14 Pricci (10.1016/j.carres.2024.109195_bib24) 2000; 58 Dam (10.1016/j.carres.2024.109195_bib23) 2005; 44 Win (10.1016/j.carres.2024.109195_bib9) 2012; 2012 Cullen (10.1016/j.carres.2024.109195_bib27) 2024 |
References_xml | – volume: 9 start-page: 835 year: 2017 ident: bib13 article-title: Food processing: the influence of the maillard reaction on immunogenicity and allergenicity of food proteins publication-title: Nutrients – volume: 372 start-page: 2229 year: 2015 end-page: 2234 ident: bib25 article-title: Precision medicine — personalized, problematic, and promising publication-title: N. Engl. J. Med. – volume: 319 start-page: C45 year: 2020 end-page: C63 ident: bib30 article-title: Thrombospondin-1 in maladaptive aging responses: a concept whose time has come publication-title: Am. J. Physiol.-Cell Physiol. – volume: 2013 start-page: 1 year: 2013 end-page: 15 ident: bib10 article-title: Receptor for advanced glycation end products and its involvement in inflammatory diseases publication-title: Intern. J Inflam – volume: 37 start-page: 657 year: 2020 end-page: 666 ident: bib35 article-title: TF-containing MUC1 glycopeptides fail to entice Galectin-1 recognition of tumor-associated Thomsen-Freidenreich (TF) antigen (CD176) in solution publication-title: Glycoconj. J. – volume: 1 start-page: 634 year: 1995 end-page: 646 ident: bib12 article-title: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex publication-title: Mol. Med. – start-page: 1 year: 2023 end-page: 15 ident: bib7 article-title: The role of the receptor for advanced glycation endproducts (RAGE) in type 1 diabetes: an immune cell perspective publication-title: Type 1 Diabetes 2023 - Real Pract – volume: 18 start-page: 1773 year: 2004 end-page: 1775 ident: bib21 article-title: Galectin‐3/AGE‐receptor 3 knockout mice show accelerated AGE‐induced glomerular injury: evidence for a protective role of galectin‐3 as an AGE receptor publication-title: FASEB J – volume: 26 start-page: 88 year: 2016 end-page: 99 ident: bib36 article-title: Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain publication-title: Glycobiology – year: 2024 Jan ident: bib27 article-title: Physiology, Enkephalin publication-title: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing – volume: 44 start-page: 12564 year: 2005 end-page: 12571 ident: bib23 article-title: Galectins bind to the multivalent glycoprotein asialofetuin with enhanced affinities and a gradient of decreasing binding constants publication-title: Biochemistry – volume: 60 start-page: 7213 year: 2017 end-page: 7232 ident: bib8 article-title: Targeting the receptor for advanced glycation endproducts (RAGE): a medicinal chemistry perspective publication-title: J. Med. Chem. – volume: 14 start-page: 253 year: 1996 end-page: 267 ident: bib32 article-title: Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs publication-title: Clin. Exp. Metastasis – volume: 439 start-page: 123 year: 2013 end-page: 131 ident: bib33 article-title: Development of an AlphaScreen assay for discovery of inhibitors of low-affinity glycan–lectin interactions publication-title: Anal. Biochem. – volume: 2 start-page: 789 year: 1996 end-page: 794 ident: bib3 article-title: Synthesis and publication-title: J Chem Soc Perkin Trans – volume: 14 start-page: 936 year: 2008 end-page: 945 ident: bib5 article-title: Fructose‐induced publication-title: J Pep Sci – volume: 343 start-page: 2475 year: 2008 end-page: 2480 ident: bib4 article-title: Glycation of a lysine-containing tetrapeptide by d-glucose and d-fructose—influence of different reaction conditions on the formation of Amadori/Heyns products publication-title: Carbohydr. Res. – volume: 23 start-page: 819 year: 2019 end-page: 828 ident: bib15 article-title: Galectin-3: is this member of a large family of multifunctional lectins (already) a therapeutic target? publication-title: Expert Opin. Ther. Targets – volume: 67 start-page: 11760 year: 2007 end-page: 11768 ident: bib18 article-title: Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers publication-title: Cancer Res. – volume: 36 start-page: 6 year: 2019 end-page: 16 ident: bib26 article-title: Glycosylation in the era of cancer-targeted therapy: where are we heading? publication-title: Cancer Cell – volume: 19 start-page: 433 year: 2002 end-page: 440 ident: bib16 article-title: Introduction to galectins publication-title: Glycoconj. J. – volume: 128 start-page: 1221 year: 1982 end-page: 1228 ident: bib17 article-title: Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies publication-title: J. Immunol. Baltim. Md 1950 – volume: 58 start-page: S31 year: 2000 end-page: S39 ident: bib24 article-title: Role of galectin-3 as a receptor for advanced glycosylation end products publication-title: Kidney Int. – volume: 285 start-page: 35079 year: 2010 end-page: 35091 ident: bib37 article-title: Mutational tuning of galectin-3 specificity and biological function publication-title: J. Biol. Chem. – volume: 25 start-page: 136 year: 2015 end-page: 150 ident: bib20 article-title: Galectin-3: an emerging all-out player in metabolic disorders and their complications publication-title: Glycobiology – volume: 14 start-page: 11 year: 2017 ident: bib22 article-title: A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus publication-title: Clin. Proteomics – volume: 54 start-page: 4462 year: 2015 end-page: 4474 ident: bib34 article-title: Thermodynamic switch in binding of adhesion/growth regulatory human galectin-3 to tumor-associated TF antigen (CD176) and MUC1 glycopeptides publication-title: Biochemistry – volume: 267 start-page: 233 year: 1990 end-page: 240 ident: bib28 article-title: The occurrence and receptor specificity of endogenous opioid peptides within the pancreas and liver of the rat publication-title: Comparison with brain, Biochem. J. – volume: 69 start-page: 421 year: 2003 end-page: 431 ident: bib2 article-title: Study of degradation pathways of Amadori compounds obtained by glycation of opioid pentapeptide and related smaller fragments: stability, reactions, and spectroscopic properties publication-title: Biopolymers – volume: 16 start-page: 210 year: 2006 end-page: 220 ident: bib14 article-title: Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis publication-title: Glycobiology – volume: 10 start-page: 3047 year: 2021 ident: bib29 article-title: Novel galectin-3 roles in neurogenesis, inflammation and neurological diseases publication-title: Cells – volume: 1379 start-page: 97 year: 1998 end-page: 106 ident: bib19 article-title: Modulation of the biological functions of galectin-3 by matrix metalloproteinases publication-title: Biochim. Biophys. Acta BBA - Gen. Subj. – volume: 18 start-page: 1342 year: 2010 end-page: 1352 ident: bib6 article-title: Structural Basis for ligand recognition and activation of RAGE publication-title: Structure – volume: 2012 start-page: 1 year: 2012 end-page: 8 ident: bib9 article-title: Regulation of RAGE for attenuating progression of diabetic vascular complications, Exp publication-title: Diabetes Res. – volume: 10 start-page: 119 year: 2004 end-page: 137 ident: bib1 article-title: Peptide and amino acid glycation: new insights into the Maillard reaction publication-title: J. Pept. Sci. – volume: 11 start-page: 1130 year: 2020 end-page: 1136 ident: bib31 article-title: Identification of inhibitors of thrombospondin 1 activation of TGF-β publication-title: ACS Med. Chem. Lett. – volume: 31 start-page: 129 year: 2017 end-page: 136 ident: bib11 article-title: Preliminary mass spectrometry characterization studies of galectin‐3 samples, prior to carbohydrate‐binding studies using Affinity mass spectrometry publication-title: Rapid Commun. Mass Spectrom. – volume: 2 start-page: 789 year: 1996 ident: 10.1016/j.carres.2024.109195_bib3 article-title: Synthesis and 13 C NMR investigation of novel Amadori compounds (1-amino-1-deoxy- D -fructose derivatives) related to the opioid peptide, leucine–enkephalin publication-title: J Chem Soc Perkin Trans doi: 10.1039/P29960000789 – volume: 2012 start-page: 1 year: 2012 ident: 10.1016/j.carres.2024.109195_bib9 article-title: Regulation of RAGE for attenuating progression of diabetic vascular complications, Exp publication-title: Diabetes Res. doi: 10.1155/2012/894605 – volume: 44 start-page: 12564 year: 2005 ident: 10.1016/j.carres.2024.109195_bib23 article-title: Galectins bind to the multivalent glycoprotein asialofetuin with enhanced affinities and a gradient of decreasing binding constants publication-title: Biochemistry doi: 10.1021/bi051144z – volume: 10 start-page: 3047 year: 2021 ident: 10.1016/j.carres.2024.109195_bib29 article-title: Novel galectin-3 roles in neurogenesis, inflammation and neurological diseases publication-title: Cells doi: 10.3390/cells10113047 – volume: 23 start-page: 819 year: 2019 ident: 10.1016/j.carres.2024.109195_bib15 article-title: Galectin-3: is this member of a large family of multifunctional lectins (already) a therapeutic target? publication-title: Expert Opin. Ther. Targets doi: 10.1080/14728222.2019.1675638 – volume: 285 start-page: 35079 year: 2010 ident: 10.1016/j.carres.2024.109195_bib37 article-title: Mutational tuning of galectin-3 specificity and biological function publication-title: J. Biol. Chem. doi: 10.1074/jbc.M109.098160 – volume: 128 start-page: 1221 year: 1982 ident: 10.1016/j.carres.2024.109195_bib17 article-title: Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies publication-title: J. Immunol. Baltim. Md 1950 – volume: 58 start-page: S31 year: 2000 ident: 10.1016/j.carres.2024.109195_bib24 article-title: Role of galectin-3 as a receptor for advanced glycosylation end products publication-title: Kidney Int. doi: 10.1046/j.1523-1755.2000.07706.x – year: 2024 ident: 10.1016/j.carres.2024.109195_bib27 article-title: Physiology, Enkephalin – volume: 1379 start-page: 97 year: 1998 ident: 10.1016/j.carres.2024.109195_bib19 article-title: Modulation of the biological functions of galectin-3 by matrix metalloproteinases publication-title: Biochim. Biophys. Acta BBA - Gen. Subj. doi: 10.1016/S0304-4165(97)00086-X – volume: 14 start-page: 936 year: 2008 ident: 10.1016/j.carres.2024.109195_bib5 article-title: Fructose‐induced N ‐terminal glycation of enkephalins and related peptides publication-title: J Pep Sci doi: 10.1002/psc.1029 – volume: 11 start-page: 1130 year: 2020 ident: 10.1016/j.carres.2024.109195_bib31 article-title: Identification of inhibitors of thrombospondin 1 activation of TGF-β publication-title: ACS Med. Chem. Lett. doi: 10.1021/acsmedchemlett.9b00540 – volume: 18 start-page: 1342 year: 2010 ident: 10.1016/j.carres.2024.109195_bib6 article-title: Structural Basis for ligand recognition and activation of RAGE publication-title: Structure doi: 10.1016/j.str.2010.05.017 – volume: 267 start-page: 233 year: 1990 ident: 10.1016/j.carres.2024.109195_bib28 article-title: The occurrence and receptor specificity of endogenous opioid peptides within the pancreas and liver of the rat publication-title: Comparison with brain, Biochem. J. – volume: 343 start-page: 2475 year: 2008 ident: 10.1016/j.carres.2024.109195_bib4 article-title: Glycation of a lysine-containing tetrapeptide by d-glucose and d-fructose—influence of different reaction conditions on the formation of Amadori/Heyns products publication-title: Carbohydr. Res. doi: 10.1016/j.carres.2008.07.003 – volume: 372 start-page: 2229 year: 2015 ident: 10.1016/j.carres.2024.109195_bib25 article-title: Precision medicine — personalized, problematic, and promising publication-title: N. Engl. J. Med. doi: 10.1056/NEJMsb1503104 – volume: 69 start-page: 421 year: 2003 ident: 10.1016/j.carres.2024.109195_bib2 article-title: Study of degradation pathways of Amadori compounds obtained by glycation of opioid pentapeptide and related smaller fragments: stability, reactions, and spectroscopic properties publication-title: Biopolymers doi: 10.1002/bip.10338 – volume: 10 start-page: 119 year: 2004 ident: 10.1016/j.carres.2024.109195_bib1 article-title: Peptide and amino acid glycation: new insights into the Maillard reaction publication-title: J. Pept. Sci. doi: 10.1002/psc.519 – volume: 60 start-page: 7213 year: 2017 ident: 10.1016/j.carres.2024.109195_bib8 article-title: Targeting the receptor for advanced glycation endproducts (RAGE): a medicinal chemistry perspective publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.7b00058 – volume: 16 start-page: 210 year: 2006 ident: 10.1016/j.carres.2024.109195_bib14 article-title: Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis publication-title: Glycobiology doi: 10.1093/glycob/cwj056 – volume: 25 start-page: 136 year: 2015 ident: 10.1016/j.carres.2024.109195_bib20 article-title: Galectin-3: an emerging all-out player in metabolic disorders and their complications publication-title: Glycobiology doi: 10.1093/glycob/cwu111 – volume: 9 start-page: 835 year: 2017 ident: 10.1016/j.carres.2024.109195_bib13 article-title: Food processing: the influence of the maillard reaction on immunogenicity and allergenicity of food proteins publication-title: Nutrients doi: 10.3390/nu9080835 – volume: 37 start-page: 657 year: 2020 ident: 10.1016/j.carres.2024.109195_bib35 article-title: TF-containing MUC1 glycopeptides fail to entice Galectin-1 recognition of tumor-associated Thomsen-Freidenreich (TF) antigen (CD176) in solution publication-title: Glycoconj. J. doi: 10.1007/s10719-020-09951-x – volume: 2013 start-page: 1 year: 2013 ident: 10.1016/j.carres.2024.109195_bib10 article-title: Receptor for advanced glycation end products and its involvement in inflammatory diseases publication-title: Intern. J Inflam – volume: 439 start-page: 123 year: 2013 ident: 10.1016/j.carres.2024.109195_bib33 article-title: Development of an AlphaScreen assay for discovery of inhibitors of low-affinity glycan–lectin interactions publication-title: Anal. Biochem. doi: 10.1016/j.ab.2013.04.028 – volume: 19 start-page: 433 year: 2002 ident: 10.1016/j.carres.2024.109195_bib16 article-title: Introduction to galectins publication-title: Glycoconj. J. doi: 10.1023/B:GLYC.0000014072.34840.04 – volume: 36 start-page: 6 year: 2019 ident: 10.1016/j.carres.2024.109195_bib26 article-title: Glycosylation in the era of cancer-targeted therapy: where are we heading? publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.06.006 – volume: 26 start-page: 88 year: 2016 ident: 10.1016/j.carres.2024.109195_bib36 article-title: Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain publication-title: Glycobiology doi: 10.1093/glycob/cwv073 – volume: 14 start-page: 253 year: 1996 ident: 10.1016/j.carres.2024.109195_bib32 article-title: Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs publication-title: Clin. Exp. Metastasis doi: 10.1007/BF00053899 – volume: 319 start-page: C45 year: 2020 ident: 10.1016/j.carres.2024.109195_bib30 article-title: Thrombospondin-1 in maladaptive aging responses: a concept whose time has come publication-title: Am. J. Physiol.-Cell Physiol. doi: 10.1152/ajpcell.00089.2020 – volume: 14 start-page: 11 year: 2017 ident: 10.1016/j.carres.2024.109195_bib22 article-title: A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus publication-title: Clin. Proteomics doi: 10.1186/s12014-017-9146-0 – volume: 67 start-page: 11760 year: 2007 ident: 10.1016/j.carres.2024.109195_bib18 article-title: Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-07-3233 – start-page: 1 year: 2023 ident: 10.1016/j.carres.2024.109195_bib7 article-title: The role of the receptor for advanced glycation endproducts (RAGE) in type 1 diabetes: an immune cell perspective – volume: 18 start-page: 1773 year: 2004 ident: 10.1016/j.carres.2024.109195_bib21 article-title: Galectin‐3/AGE‐receptor 3 knockout mice show accelerated AGE‐induced glomerular injury: evidence for a protective role of galectin‐3 as an AGE receptor publication-title: FASEB J doi: 10.1096/fj.04-2031fje – volume: 1 start-page: 634 year: 1995 ident: 10.1016/j.carres.2024.109195_bib12 article-title: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex publication-title: Mol. Med. doi: 10.1007/BF03401604 – volume: 54 start-page: 4462 year: 2015 ident: 10.1016/j.carres.2024.109195_bib34 article-title: Thermodynamic switch in binding of adhesion/growth regulatory human galectin-3 to tumor-associated TF antigen (CD176) and MUC1 glycopeptides publication-title: Biochemistry doi: 10.1021/acs.biochem.5b00555 – volume: 31 start-page: 129 year: 2017 ident: 10.1016/j.carres.2024.109195_bib11 article-title: Preliminary mass spectrometry characterization studies of galectin‐3 samples, prior to carbohydrate‐binding studies using Affinity mass spectrometry publication-title: Rapid Commun. Mass Spectrom. doi: 10.1002/rcm.7775 |
SSID | ssj0000676 |
Score | 2.4380863 |
Snippet | Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 109195 |
SubjectTerms | AlphaScreen Amadori compounds amino acid sequences Blood Proteins enkephalin Enkephalin, Leucine - chemistry Enkephalin, Leucine - metabolism Enkephalins - chemistry Enkephalins - metabolism Galectin 3 - chemistry Galectin 3 - metabolism Galectin-3 galectins Galectins - chemistry Galectins - metabolism Heyns compounds Humans Leu-enkephalin Ligands Maillard reaction moieties pathogenesis Peptides - chemistry Protein Binding sugars |
Title | Amadori and Heyns rearrangement products of bioactive peptides as potential new ligands of galectin-3 |
URI | https://dx.doi.org/10.1016/j.carres.2024.109195 https://www.ncbi.nlm.nih.gov/pubmed/38908217 https://www.proquest.com/docview/3071283311 https://www.proquest.com/docview/3153664907 |
Volume | 542 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NS8NAEF1ED3oRv61frOB1tWm2SXMsRakWPYiit2WT7EpEk9DUgxd_u_OyiSj4AZ5Ky4Qss5t5j_TNG8aOUnqAIl8bIcMkFHCYE4MBZGLWRjogPIpqx5vLq2B8Ky_u-_dzbNT2wkBW2dR-V9Prat38ctJk86TMMvT4go4T_kiUWolGcylDnPLjN-9zNQ4cBR4IRLftc7XGK4EcFqbdPQlfJQ9TJr6Hp5_oZw1DZytsueGPfOiWuMrmTL7GFkft2LZ1ZobPOi2mGdd5ysfmNa_4FHpcNBHgTSAvncdrxQvL46zQdcHjJdQtqam4rnhZzKAhotsQ5-ZP2QPagREONKHwXPgb7Pbs9GY0Fs0sBZH4UX8mrB_CeAbm-ZooWI-YiSVyAr-vbkoPsQnlwCZp2of7T2zg8xVgHllkegYcyt9k83mRm23Gte3plFhVTExIStsnxuvZiJAuNt0o8ZIO89sUqqQxGse8iyfVKsoelUu8QuKVS3yHiY-rSme08Ud82O6O-nJgFGHBH1cetpupaG_wB4nOTfFSKap3BNe-73m_xBBEBIGMumGHbbmT8LFeShcxKi_c-ffadtkSvjmF4R6bn01fzD6xnll8UB_rA7YwPJ-Mr_A5ub6bvAOvTgAV |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT4NAEJ5oe6gX49v6XBOvG0tZoBybRoOP9qRJb5sFdg1GgZR68N87w4LRxEfiFXbDZnaZ7wt88w3AeYovUOgqzUWQBJwc5vhoRDIxY0LlIx6FtePNdOZHD-Jm7s1XYNLWwpCsssn9NqfX2bq5ctFE86LMMqrxJTqO-CMo1QpvFbrkTuV1oDu-vo1mnxOyb1nwiNOEtoKulnklpIgl3-6hIGslhxpNfI9QPzHQGomuNmC9oZBsbFe5CSs634LepO3ctg16_KLSYpExlacs0m95xRYkyaU6AvoYyEpr81qxwrA4K1Sd81hJApdUV0xVrCyWJCPCxyDtZs_ZI1UE03ACFByec3cHHq4u7ycRb9op8MQNvSU3bkDeM-Sfr5CFDZGcGOQnZPk1SPE91oEYmSRNPTIAijVZffnUkizUQ000yt2FTl7keh-YMkOVIrGKkQwJYTwkvY4JEexiPQgTJ-mD24ZQJo3XOLW8eJatqOxJ2sBLCry0ge8D_5hVWq-NP8YH7e7IL2dGIhz8MfOs3UyJe0P_SFSui9dKYspDxHZdx_llDKKE74twEPRhz56Ej_ViuJBUOcHBv9d2Cr3ofnon765nt4ewRnes4PAIOsvFqz5GErSMT5pD_g5t3AEj |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Amadori+and+Heyns+rearrangement+products+of+bioactive+peptides+as+potential+new+ligands+of+galectin-3&rft.jtitle=Carbohydrate+research&rft.au=Jakas%2C+Andreja&rft.au=Ayyalasomayajula%2C+Ramya&rft.au=Cudic%2C+Mare&rft.date=2024-08-01&rft.issn=0008-6215&rft_id=info:doi/10.1016%2Fj.carres.2024.109195&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-6215&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-6215&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-6215&client=summon |